ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL48361
CHEMBL48361
Compound Name DABIGATRAN
ChEMBL Synonyms Dabigatran | BIBR 953 ZW | BIBR-953 | PRADAXA
Max Phase 3
Trade Names
Molecular Formula C25H25N7O3

Additional synonyms for CHEMBL48361 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES Cn1c(CNc2ccc(cc2)C(=N)N)nc3cc(ccc13)C(=O)N(CCC(=O)O)c4ccccn4
Standard InChI InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34 ...
Download InChI
Standard InChI Key YBSJFWOBGCMAKL-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • Clinical Candidates
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names

Alternate Forms of Compound in ChEMBL


CHEMBL48361

Molecule Features

CHEMBL48361 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Unclassified Parenteral:Unclassified Topical:Unclassified Black Box:Unclassified Availability Type:Unclassified

Mechanism of Action

Mechanism of Action ChEMBL Target References
Thrombin inhibitor Thrombin PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
DiseaseD004194EFO:0000408disease2ClinicalTrials
CADASILD046589Orphanet:136CADASIL2ClinicalTrials
Renal InsufficiencyD0514371ClinicalTrials
Wounds and InjuriesD014947EFO:0000546injury3ClinicalTrials
Atrial FibrillationD001281EFO:0000275atrial fibrillation3ClinicalTrials
Venous ThromboembolismD054556EFO:0004286venous thromboembolism3ClinicalTrials

Clinical Data

ClinicalTrials.gov DABIGATRAN
The Cochrane Collaboration DABIGATRAN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL48361. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL204 Thrombin Homo sapiens 1.000
CHEMBL3769 Trypsin I Bos taurus 1.000
CHEMBL3959 Quinone reductase 2 Homo sapiens 0.997
CHEMBL2079849 Serine protease hepsin Homo sapiens 0.571
CHEMBL209 Trypsin I Homo sapiens 0.281

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL204 Thrombin Homo sapiens 1.000
CHEMBL3769 Trypsin I Bos taurus 0.997
CHEMBL3959 Quinone reductase 2 Homo sapiens 0.993
CHEMBL1743122 Solute carrier family 22 member 2 Homo sapiens 0.650
CHEMBL209 Trypsin I Homo sapiens 0.402

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
471.5 471.2019 2.99 9 150.22 ZWITTERION


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 4 0 10 5 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
4.17 12.62 1.02 -1.48 4 35 0.22

Structural Alerts

There are 6 structural alerts for CHEMBL48361. To view alerts please click here.

Compound Cross References

ChemSpider ChemSpider:YBSJFWOBGCMAKL-UHFFFAOYSA-N
PubChem SID: 174006835
Wikipedia Dabigatran

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL48361



ACToR 211914-51-1
BindingDB 50112086
Brenda 167473
ChEBI 70752
ChemicalBook CB61458206
eMolecules 31592368
EPA CompTox Dashboard DTXSID50175419
FDA SRS I0VM4M70GC
Guide to Pharmacology 6380
IBM Patent System 243A07EE8DB387306426E89FCDFB4865
MolPort MolPort-008-155-829
Nikkaji J3.014.665D
PDBe 4CC
PubChem 216210
PubChem: Drugs of the Future 12015494
PubChem: Thomson Pharma 14883023
Selleck BIBR-953(Dabigatran)
SureChEMBL SCHEMBL3573
ZINC ZINC000001910616

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/YBSJFWOBGCMAKL-UHFFFAOYSA-N spacer
spacer